EnteroMedics (ETRM) : During the past 4 weeks, traders have been relatively bearish on EnteroMedics (ETRM), hence the stock is down -35.54% when compared to the S&P 500 during the same period. However, in the past 1 week, the selling of the stock is down by -9.09% relative to the S&P 500. The 4-week change in the price of the stock is -34.88% and the stock has fallen -9.04% in the past 1 week.
The stock has recorded a 20-day Moving Average of 18.85% and the 50-Day Moving Average is 44.82%. EnteroMedics (NASDAQ:ETRM): On Fridays trading session , Opening price of the stock was $0.175 with an intraday high of $0.1789. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $0.1657. However, the stock managed to close at $0.169, a loss of 1.69% for the day. On the previous day, the stock had closed at $0.1719. The total traded volume of the day was 1,574,459 shares.
The company Insiders own 13.7% of EnteroMedics shares according to the proxy statements. In the past twelve weeks, the net percent change held by company insiders has changed by 271.26% . Institutional Investors own 12.11% of EnteroMedics shares. During last six month period, the net percent change held by insiders has seen a change of 271.26%. Also, In a research note released to the investors, Roth Capital downgrades its rating on EnteroMedics (NASDAQ:ETRM).The analysts at the brokerage house have a current rating of Neutral on the shares. Earlier, the shares were rated a Buy by the brokerage firm. In a recent information released to the investors, Roth Capital lowers the new price target from $3 per share to $0.5 per share. The rating by the firm was issued on June 9, 2016.
EnteroMedics Inc. (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Companys neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve using high frequency, low energy, electrical impulses. The Companys initial product is the Maestro System, which uses VBLOC therapy to affect metabolic regulatory control, limits the expansion of the stomach, help control hunger sensations between meals, reduce the frequency and intensity of stomach contractions and produce a feeling of early and prolonged fullness. The Company has approvals to commercially launch its product, the Maestro Rechargeable System, in the United States, Australia, the European Economic Area and other countries.